A5031817257- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Cancer-related cognitive impairment studies
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Single-cell and spatial transcriptomics
- Prostate Cancer Treatment and Research
- Streptococcal Infections and Treatments
- Ottoman and Turkish Studies
- Liver Diseases and Immunity
- Byzantine Studies and History
Princess Margaret Cancer Centre
2016-2025
University Health Network
2014-2025
University of Toronto
2012-2025
Seattle University
2024
Ontario Institute for Cancer Research
2024
Weatherford College
2022
Massachusetts Department of Mental Health
2015
The University of Sydney
2015
Lunenfeld-Tanenbaum Research Institute
2015
Mount Sinai Hospital
2009-2015
Purpose: To perform real-time whole genome sequencing (WGS) and RNA (RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive mutational transcriptional features for better treatment selection.Experimental Design: Patients with PDAC were prospectively recruited prior first-line combination chemotherapy. Fresh tumor tissue was acquired by image-guided percutaneous core biopsy WGS RNASeq. Laser capture microdissection performed all cases. Primary endpoint feasibility...
Purpose The main purpose of this study was to determine the prevalence pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort patients with pancreatic ductal adenocarcinoma describe clinical family history characteristics. Patients Methods Unselected, consecutive, incident were recruited at single cancer center over 2-year period. Participants provided blood for DNA analysis history, treatment records reviewed. from all analyzed by Sanger sequencing multiplex...
Abstract Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within COMPASS trial, patients proceeding chemotherapy for PDAC undergo tumor biopsy RNA-sequencing (RNA-seq). Overall response rate (ORR) overall survival (OS) were stratified by according received. Correlation with using gene profiling, situ hybridization (ISH) was explored. Results:...
Cognitive dysfunction is reported in people with cancer. Therefore, we evaluated longitudinal changes cognitive function and underlying mechanisms colorectal cancer (CRC) healthy controls (HCs).Participants completed assessments questionnaires reporting symptoms, fatigue, quality of life, anxiety/depression at baseline (before chemotherapy, if given) 6, 12, 24 months. Blood tests included cytokines, clotting factors, apolipoprotein E genotype, sex hormones. Primary end point was overall...
To describe the clinical, pathological and genomic characteristics of pancreatic cancer with DNA mismatch repair deficiency (MMRD) proficiency (MMRP).We identified patients MMRD MMRP in a clinical cohort (N=1213, 519 genetic testing, 53 immunohistochemistry (IHC)) (N=288 whole-genome sequencing (WGS)).12 out 1213 (1.0%) were by IHC or WGS. Of 14 Lynch syndrome, 3 (21.4%) had an IHC, 4 (28.6%) excluded because tissue was unavailable for testing. cancers longer overall survival after surgery...
602 Background: Combination approaches of immune-checkpoint inhibitors and locoregional therapies have an increasing role in advanced HCC. Methods: The PEMRAD phase II trial investigated the efficacy combination pembrolizumab stereotactic body radiation (SBRT) following progression on sorafenib. Patients with HCC, ECOG 0-1 Childs-Pugh A were eligible. received day 1 followed by SBRT starting Day 2 delivered five fractions. Pembrolizumab was continued every 21 days until progression,...
559 Background: Biliary tract cancers (BTC) are rare but have been implicated in hereditary cancer conditions such as Lynch syndrome (LS) and BRCA1 BRCA2. Data from paired somatic germline genetic testing on BTC shown that ~5% may be related to pathogenic variants Identification of these (PV) often provide patients with an opportunity for personalized treatment including platinum-based chemotherapies, PARP inhibitors and/or immunotherapy. Germline also provides crucial data relatives...
765 Background: In resected pancreatic cancer (PDA), morphology from routine histopathology slides provides a rapid inexpensive biomarker that predicts overall survival and correlates with transcriptomic subtypes. this study, we evaluated clinical genomic associations of morphological subtypes in advanced disease validated the consistency patient-derived organoids (PDO) mouse xenografts (PDXs) during vitro vivo modeling. Methods: Our cohort included PDA tumor tissues 152 resectable (stage...
751 Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a hypercoagulable state leading to thrombosis. Risk models such as the Khorana score automatically classify PDAC intermediate-high risk, and recent guidelines recommend consideration of thromboprophylaxis. However, little known about molecular correlates for venous thromboembolism (VTE). Methods: We examined clinical genomic data from prospective multi-institution COMPASS trial (NCT02750657), which enrolled patients...
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at large Canadian academic center. We characterized proportion targetable alterations, treatment recommendations generated by tumor board,...
FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic We present a retrospective study patients with cancer using as first-line therapy our centre.This review treated for at Princess Margaret Cancer Centre, between December 2011 July 2014. The primary objective was evaluate efficacy safety when used dose modifications.One hundred two...
Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.COMPASS prospective observational trial PDAC. A biopsy required prior initiating chemotherapy, determined by...
Abstract Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that recapitulate the genotypic phenotypic landscape of patient cancers could help to advance research lead improved clinical management. PDX were established from 276 pancreato-duodenal biliary cancer resections. Initial, passage 0 (P0) engraftment rates 59% (118/199) for pancreatic, 86% (25/29) duodenal, 35% (17/48) ductal tumors. Pancreatic adenocarcinoma (PDAC), had a P0 rate 62% (105/169). KRAS...
TPS635 Background: Over 70% of patients with pancreatic ductal adenocarcinoma (PDAC) present metastatic disease where the mainstay treatment is combination chemotherapy. Two pivotal phase III trials showed survival benefit mFOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP), respectively, compared to gemcitabine alone. Both are considered standard 1st line options but have not been prospectively. Other than BRCA phenotype there no predictive molecular markers identify which will from...
LBA4004 Background: Over 60% of patients with pancreatic ductal adenocarcinoma (PDAC) present metastatic disease. Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) are first-line options in advanced PDAC, however have not been compared prospectively North American patients. Moreover, biomarkers to guide selection lacking. Basal-like Classical subtypes prognostic, but their predictive impact is unknown. Patient-derived organoids (PDOs) now feasible study for drug...